Liel Y, Marbach M, Aflalo L, Glick S M, Levy J
Biochem Pharmacol. 1982 Mar 1;31(5):707-10. doi: 10.1016/0006-2952(82)90454-3.
The competition of bromocriptine and lisuride hydrogen maleate (LIM) with estradiol binding to various tissues was evaluated by the dextran coated charcoal method. Bromocriptine and LIM competitively inhibited the binding of [3H] estradiol to its cytosolic receptors in rat uterine, pituitary and hypothalamic tissue and in DMBA induced mammary tumors. Ki was 2 X 10(-5) M for bromocriptine and 2 X 10(-4) M for LIM. Metoclopramide, dopamine and L-dopa had no significant effect on [3H] estradiol binding. The interaction of bromocriptine and LIM was specific for estrogen receptors. There was no interaction with progesterone receptors from rat uterus and pituitary and with testosterone receptors from rat epididymis and testis. When tested for estrogenity in the immature rat uterus, bromocriptine and LIM induced specific estrogen inducible proteins such as cytosolic estrogen and progesterone receptors. However, they do not affect the uterine/body weight ratio and peroxidase activity. A clear interaction of inhibitors (bromocriptine and LIM) of prolactine secretion, with cytosolic estrogen receptors from various tissues was shown. Some in vivo estrogenic effect was also demonstrated in the immature rat uterine system.
采用葡聚糖包被活性炭法评估了溴隐亭和马来酸麦角乙脲(LIM)与雌二醇结合至各种组织的竞争情况。溴隐亭和LIM竞争性抑制[³H]雌二醇与其在大鼠子宫、垂体、下丘脑组织以及二甲基苯蒽诱导的乳腺肿瘤中的胞质受体的结合。溴隐亭的Ki为2×10⁻⁵M,LIM的Ki为2×10⁻⁴M。甲氧氯普胺、多巴胺和左旋多巴对[³H]雌二醇的结合无显著影响。溴隐亭和LIM的相互作用对雌激素受体具有特异性。与大鼠子宫和垂体的孕激素受体以及大鼠附睾和睾丸的雄激素受体无相互作用。当在未成熟大鼠子宫中检测雌激素活性时,溴隐亭和LIM诱导了特异性雌激素诱导蛋白,如胞质雌激素和孕激素受体。然而,它们不影响子宫/体重比和过氧化物酶活性。显示了催乳素分泌抑制剂(溴隐亭和LIM)与各种组织的胞质雌激素受体之间存在明显的相互作用。在未成熟大鼠子宫系统中也证实了一些体内雌激素效应。